AliveCor, Inc has been ranked the number one company utilising artificial intelligence within the healthcare industry.
To produce its 2018 list, Fast Company has surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture.
Ranked third out of the health category last year, its move to the number one position in the AI category highlights how its FDA-cleared machine learning techniques have provided proactive heart and cardiac care across a number of technologies.
The company also ranked 20th overall in an evaluation of thousands of companies worldwide in Fast Company's Top 50 Most Innovative Companies in the World.
The FDA-cleared KardiaMobile is the most clinically validated mobile EKG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG.
Kardia is the first AI enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. KardiaBand is the first FDA-cleared medical device accessory for Apple Watch Series 1,2 and 3, which will support the detection of abnormal heart murmurs through the use of electrode sensors.
Utilising AI, cloud and micro-electrode technology to advance the state of the art in cardiac care, AliveCor empowers people to proactively manage heart health and improve the quality of care in the fight against heart disease. Its deep neural network assesses heart rate data, as well as physical activity and other influencing factors, to help patients develop deeper insights into their heart rhythm.
Over time, AliveCor's analysis of biometric data will work to evaluate a range of serious heart conditions and even changes in blood chemistry through AI software, SmartRhythm. The use of AI will help add meaning to patient data, and facilitate important improvements in insights, therapies, and procedures.